Results regarding a direct effect of catecholamines or βAR agonists on cancer cells are thus conflicting, but this is to be expected based on the in vitro nature of these assays, the focus on unique cell lines with specific characteristics, and the different doses of drugs used. Here, ADRB2 is linked to cancer.